Related Experiment Video
Updated: May 21, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells
ZhaoYun Liu1, Jiao Lai1, Chun Yang1
1Department of Hematology, Tianjin Medical University General Hospital, 154 Anshan Street, Heping District, Tianjin 300052, China, Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin Institute of Hematology, State Key Laboratory of Experimental Hematology.
None:
Bone marrow plasma cells proliferate malignantly in multiple myeloma (MM), a hematological cancer. MM is now the second most common hematologic illness, followed by non-Hodgkin's lymphoma. The tumor microenvironment (TME) is a crucial factor in MM development. T cells, natural killer (NK) cells, and natural killer T (NKT) cells are the key anti-MM immune cells in the bone marrow microenvironment (BMME). By direct contact or cytokine production, these cells prevent MM cells from proliferation and survival. However, a major factor contributing to the insufficiency of anti-tumor immune responses is the inhibition of T cells and NK cells functions. We aimed to summarize the mechanisms of T cells and NK cells suppression in MM and discuss emerging immunotherapies that target both cell types.
Related Concept Videos
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

